A 54-Week, Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (Expedition Lead-in) (Expedition)

  • End date
    Apr 22, 2024
  • participants needed
  • sponsor
Updated on 28 October 2022
AstraZeneca Clinical Study Information Center
Primary Contact
Research Site (0.4 mi away) Contact
+73 other location
ulcerative colitis
rectal bleeding


The present study (D5272C00001/Legacy #3151-201-008) aims to evaluate the efficacy and safety of brazikumab in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy.

Condition Ulcerative Colitis, IBD
Treatment Placebo, Vedolizumab, Brazikumab
Clinical Study IdentifierNCT03616821
Last Modified on28 October 2022


Yes No Not Sure

Inclusion Criteria

Ability to provide informed consent
Aged 18 to 80 years of age
Diagnosis of UC with an onset of symptoms for a minimum of 3 months prior to Screening
Evidence of UC extending proximal to the rectum (≥ 15 cm of involved colon)
Moderately to severely active UC as defined by
Average daily mMS Stool Frequency subscore ≥ 1 AND Average daily mMS Rectal Bleeding subscore ≥ 1
Modified Mayo endoscopic subscore of ≥ 2 based on a full colonoscopy within 14 days prior to randomization
Participant had an inadequate response or intolerance to intervention with
conventional treatment or prior biological treatment or demonstrated CS
Participants taking 5-aminosalicylates, oral prednisone (or equivalent), oral budesonide, or immunomodulators must be at a stable dose or discontinued. Topical (rectal) aminosalicylic acid or topical (rectal) steroids should be discontinued
dependence for the treatment of UC. For participants who have previously used
Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal
biological treatment, a participant may have failed up to 3 biologics that
Non sterilized males who are sexually active with a female partner of childbearing potential should use condoms during treatment and until the end of relevant systemic exposure in the male participant, plus a further 18 weeks
include up to 2 different mechanisms of action
Complete inclusion criteria are in the Clinical Study Protocol
Female participants of childbearing potential must have a negative urine pregnancy test prior to administration of study intervention and must agree to use a highly effective method of birth control throughout the study and for at least 18 weeks after the last dose of study intervention
No known history of active TB or latent TB without completion of appropriate intervention and negative QFT-TB during Screening

Exclusion Criteria

Clinically significant cardiovascular conditions
Participant has UC limited to the rectum (ie, not beyond 15 cm of the anal verge)
Current diagnosis of fulminant colitis, a diagnosis of CD or indeterminate colitis, presence or history of a fistula consistent with CD, primary sclerosing cholangitis, celiac disease, or untreated bile acid malabsorption. Participants with a history of toxic megacolon within 12 months of screening are excluded
History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, ileostomy, or other prior colonic resection, or need for surgical intervention for control of UC anticipated within 6 months
Participant has received the following treatment
Infliximab: within 8 weeks prior to randomization
Adalimumab, certolizumab pegol, or golimumab: within 8 weeks prior to randomization
Vedolizumab or ustekinumab within 12 weeks of randomization
Other prohibited medication, biologic or small molecule treatment within 5 half-lives prior to randomization
Fecal microbiota transplantation: within 8 weeks prior to randomization
Except for ustekinumab, prior exposure to any biologic agent targeting IL-12 or IL-23
Known history of allergy to the study intervention formulation or any of its excipients or components of the delivery device, or to any other biologic therapy
Participant received cyclosporine, mycophenolate mofetil, sirolimus (rapamycin), thalidomide, tacrolimus (FK-506), or tofacitinib within 2 weeks prior to Screening
Participants who received IV or intramuscular steroids within 2 weeks prior to Screening
Criterion deleted as part of Amendment 5 v6.0
Participant is currently enrolled in another investigational device or drug study, or is within 35 days or 5 half-lives, whichever is longer, since ending another investigational device or drug study(s), or receiving other investigational agent(s)
Participant received a transfusion of blood, plasma, or platelets within 30 days prior to Screening
Participant has any of the following criteria related to infections
Evidence of a recent systemic fungal infection, requiring inpatient hospitalization, and/or antifungal treatment
Any infection requiring hospitalization or treatment with IV anti-infectives within 4 weeks of Screening
Participant received a Bacille Calmette-Guérin vaccination within 12 months of randomization or any other live vaccine less than 4 weeks prior to randomization
Cytomegalovirus or Epstein-Barr virus infection that has not resolved within 8 weeks prior to Screening
Clinically significant chronic infection that has not resolved within 8 weeks of Screening
Nonserious infection requiring oral anti-infectives within 2 weeks prior to randomization must be further discussed with study medical monitor
Clinical evidence of or suspected to have an abscess during Screening
Any underlying condition that predisposes the participant to infections
Participant had previous allogenic bone marrow transplant or history of organ or cell-based transplantation
Clinically significant active infection or signs/symptoms of infection that has the potential to worsen with immunosuppressive therapy
Signs or symptoms of ongoing infection due to intestinal pathogens
History of cancer with the following exceptions: history of basal cell carcinoma and/or squamous cell carcinoma of the skin OR carcinoma in situ of the cervix; with apparent successful curative therapy, greater than 12 months prior to Screening
Prolonged QTcF interval or conditions leading to additional risk for QT prolongation
Clinically significant kidney disease
Participant has known or suspected history of chronic use of NSAIDs and/or opiates
Abnormal laboratory results at Screening as defined in the study protocol
drug, or alcohol abuse
Participant is pregnant or breastfeeding or plans to become pregnant during the study
Participant has other known, pre-existing, clinically significant medical conditions that are not associated with UC and are uncontrolled with standard treatment
Participant has any disorder that may compromise the ability of the participant to give written informed consent and/or to comply with all required study procedures
Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals
Complete exclusion criteria are in the Clinical Study Protocol
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note